Drugs / Autologous TIL
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05869539 | Jun 2023 → Apr 2026 overdue | melanoma | University Hospital, Basel, Switzerland | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04165967 | Sep 2020 → Mar 2023 | melanoma | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous TIL | “Day 0: Autologous TIL: (minimum 5 x 109 and up to a maximum of 2 x 1011 lymphocytes) administered intravenously over 20 to 30 minutes.” NCT04165967 ↗1“Autologous TIL: (minimum 5 x 10\^9 and up to 2x 10\^11 lymphocytes) administered intravenously over 20 to 30 minutes.” NCT05869539 ↗ |
| Modality | Cell therapy | “Adoptive cell therapy” NCT04165967 ↗ |
| Route | Intravenous | “administered intravenously over 20 to 30 minutes.” NCT04165967 ↗ |